We identified eight patients whose sera contained autoantibodies to the U2 small nuclear ribonucleoprotein (snRNP), an RNA protein particle involved in the splicing of newly transcribed messenger RNA. Each of these patients had an overlap syndrome that included features of either systemic lupus erythematosus (SLE), scleroderma, and/or polymyositis. We then used these sera to characterize the autoantigenic polypeptides of the U1 and U2 snRNP particles. In immunoblots, all sera contained antibodies to the Be polypeptide of the U2 snRNP. A subset of these sera that more effectively immunoprecipitated the native U2 particle contained gn additional antibody system that recognized the A' polypeptide of this snRNP. Antibodies eluted from the B" protein bound the A polypeptide of the U1 snRNP and vice versa. Moreover, antibodies to the Be polypeptide were accompanied by antibodies to the 68K and C polypeptides of the Ul snRNP. Finally, the A' and BT polypeptides remained physically associated after the U2 particle was cleaved with RNase.
Introduction
The U series of small nuclear ribonucIeoprotein (snRNP)' particles consists of uridine-rich, small RNAs and associated polypeptides. The abundant U I and U2 snRNPs, as well as the less abundant' U4, U5, and U6 snRNPs, are central elements 1. Abbreviations used in this paper: CPK, creatine phosphokinase; MCTD, mixed connective tissue disease; SLE, systemic lupus erythematosus; snRNP, small nuclear ribonucleoprotein.
These structures are common targets of autoimmunity in systemic lupus erythematosus (SLE) and related connective tissue disease syndromes (3, 4) .
Structurally, the Ul snRNP consists of the U I small RNA and at least nine associated polypeptides (3, (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Three of these proteins, known as 68K (Mr = 68,000 D),2 A (Mr = 33,000 D), and C (Mr = 22,000 D) are unique to the U1 snRNP. Six additional polypeptides, B' (Mr = 29,000 D), B (Mr = 28,000 D), D (Mr = 16,000 D), and E-G (M, = 13,000-11,000 D) are common to the U 1, U2, and U4-U6 snRNPs. Anti-Ul RNP antibodies bind the Ul snRNP specific polypeptides 68K, A, and/or C while anti-Sm antibodies bind a shared epitope(s) of the B', B, and D polypeptides. The E-G polypeptides are rarely autoantigenic (16) . High titers of anti-U 1 RNP antibodies are a hallmark of mixed connective tissue disease (MCTD) (19) (20) (21) (22) (23) ; in lower titers, they are also common in SLE, although often in conjunction with anti-Sm antibodies (21-24). The latter are pathognomonic for SLE.
The U2 snRNP consists of the U2 small RNA, six shared polypeptides noted above (B', B, D-G), and two unique polypeptides known as A' (Mr = 31,000 D) and Be (Mr = 28,500 D) (9, 12-14, 18, 25, 26) . Anti-U2 antibodies specific for the A' and Be polypeptides were initially described by Mimori and co-workers in 1984 in one patient with scleroderma-polymyositis overlap syndrome (25) . More recently, anti-U2 antibodies have been described in an additional four patients without an identified disease association (26) , and two patients with psoriasis and Raynaud's phenomenon (27) . Finally, Pettersson and colleagues have identified anti-U2 RNP antibodies,in the sera of six patients with MCTD (28) .
These observations raised the possibility that anti-U2 RNP antibodies might be markers for a particular subset ofpatients. To explore this possibility further, we sought these antibodies in sera from 229 patients with various rheumatic diseases. Our results demonstrate that anti-U2 antibodies exhibit linkage with anti-U1 RNP antibodies and occur mainly in sera from patients with overlap syndromes that often includes myositis. Two types of anti-U2 specific sera were identified: one class contained antibodies directed against the Be polypeptide alone, the other contained antibodies to both the A' and Be polypeptides.
Methods
Sera. Sera were obtained from 229 patients (125 Japanese, 104 American) with connective tissue diseases. One of these sera (from patient Ya; serum 4 in Table II ) is the prototype anti-U2 RNP serum first identified by Mimori et al. (25) ; two sera with known anti-U2 antibodies were obtained from other investigators. Patients with SLE and scleroderma met revised and preliminary American Rheumatism As-sociation (ARA) criteria, respectively (29, 30) . The diagnoses of MCTD and polymyositis were based upon accepted clinical criteria (20, 28, 31) and, in addition for MCTD, the presence of anti-RNP autoantibodies without anti-Sm by double immunodiffusion. Patients with other overlap syndromes met criteria for SLE and/or scleroderma and had evidence for myositis, as determined by proximal muscle weakness and elevated creatine phosphokinase (CPK) levels. As an initial screen, all sera were assayed by immunoprecipitation of 32P-labeled HeLa cell extracts (3) .
Immunofluorescence and immunodiffusion. Indirect immunofluorescence using commercial Hep-2 cell substrates (Immunoconcepts, Sacramento, CA) (25) and Otichterlony double immunodiffusion using calf thymus extract were performed as previously outlined (32) .
Preparation of radiolabeled cell extracts. HeLa cells were maihtained and radiolabeled as previously described (25) 12 ,000 g for 20 min and the supernatants were used immediately as a source of antigen.
Immunoprecipitation procedures. Immunoprecipitation ofradiolabeled cell extracts was performed as described (3, 11, 25) with modifications (33). 10 M1 ofpatient serum was incubated overnight at 4 C with 2 mg of preswollen protein A-Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) in 500 M ofimmunoprecipitation buffer (IPP: 10 mM Tris-HCl, 500 mM NaCI, 0.1% Nonidet P-40, pH 7.5). Antibodycoated beads were then washed three times in IPP and resuspended in 400 Ml of NET-2. In certain experiments, patient sera were diluted 1:100 and 1:1,000 in IPP before incubation with the protein A-Sepharose beads. For analysis of nucleic acids, beads were combined with 100 Ml of32P-labeled extract (2 X 106 cells) and incubated with rotation for 1 h at 4 C. After three washes with NET-2, the beads were resuspended in 300 M of this buffer, Preparation ofsubstratesfor immunoblots. Enriched snRNPs were prepared by immunoaffinity chromatography as described (17) with modifications. HeLa cells (7;5 X l10 cells/ml) were harvested, washed in cold Tris-buffered saline, and sonicated in 0.35 M NaCl, 10 mM Tris-HCl (pH 7.5), 1.5 mM MgCI2, and 0.2 mM phenylmethylsulfonyl fluoride. The extract was centrifuged at 10,000 g for 2 h. Supernatants were then passed through Affi-Gel 10 (Bio-Rad Laboratories, lichmond, CA) columns previously coupled with human IgG (5-7 mg/ml wet gel) isolated from patient sera with high activity of anti-U2 (patient 1, Table II), anti-U I RNP, or anti-Sm. After washing, bound material was eluted from columns with 6 M urea, 0.1 M NaCl, and 10 mM Tris-HC1 (pH 7.5). Eluted material was then concentrated by the addition of 100% TCA (final concentration 25%) followed by two cold acetone washes or by precipitation with 95% cold ethanol. After dessication, precipitated samples were then dissolved in SDS-sample buffer, heated to 90'C for five minutes, and used as substrates for immunoblots.
Immunoblots. snRNP proteins were fractionated on 12.5% SDS gels, transferred to nitrocellulose sheets (Schleicher & Schuell, Inc., Keene, NH) by electrophoresis in a buffer containing 25 mM Tris, 192 mM glycine, 0.1% SDS, and 25% methanol (16, 25, 35) . Nitrocellulose sheets were then blocked for at least I h in phosphate-buffered saline (PBS: 150 mM NaCI, 10 mM phosphate, pH 7.4) containing 3% bovine serum albumin (BSA; RIA grade; Sigma Chemical Co.) and 1% human hemoglobin (Sigma Chemical Co.). After rinsing in PBS, nitrocellulose papers were incubated in patient and control sera diluted 1:100 in PBS-0.05% Tween 20 (PBS-T) for 45 min. Strips were then washed in PBS-T, incubated with '251-labeled protein A in PBS-T (2 X 10s cpm/ml) for 45 min, rewashed, dried, and exposed to XRP film (Eastman Kodak Co., Rochester, NY) overnight at -70°C. A known positive control serum and a serum from a normal volunteer were included with each immunoblot.
Elution of antibodies from immunoblots. In certain experiments, antibodies bound to protein bands on nitrocellulose strips were eluted as previously described (36) . As controls, antibodies were eluted from areas of nitrocellulose that did not contain protein bands (blank areas) or from bands not containing U 1 or U2 snRNP proteins.
Two-dimensional immunoblots. Ethanol-precipitated snRNP proteins were fractionated for 1,500 V-h by nonequilibrium pH gradient electrophoresis as previously described (37) . Second-dimension electrophoresis was via 10% SDS-polyacrylamide gels. For comparison, snRNP polypeptides were fractionated in one dimension on the same gel. Immunoblots were performed as outlined above, except that some nitrocellulose strips were probed sequentially with two sera ofdifferent antibody specificities. In these experiments, specific IgG from the first serum was detected by '251-protein A and autoradiography. Nitrocellulose papers were then rehydrated in PBS, blocked again in BSA-hemoglobin, exposed to the second serum and '25I-labeled protein A, and autoradiography performed a second time.
Results
Initial screenfor anti-U2 antibodies. Among 229 patients with various rheumatic diseases we identified eight whose sera immunoprecipitated both Ul and U2 snRNPs from extracts of 32P-labeled HeLa cells (Fig. 1) . A control anti-U 1 RNP serum (lane 3) only immunoprecipitated the U 1 RNA (via binding to proteins that are unique to the U1 snRNP particle) while a control anti-Sm serum (lane 4) immunoprecipitated the U2, U 1, and U4-6 RNAs (via recognition of the B'/B and D polypeptides that are common to all five of these snRNP particles). In contrast, seven of the eight test sera only immunoprecipitated the Ul and U2 snRNPs (sera 1, 2, and 4-8; lanes 5-10 and lanes [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . This observation suggested that these sera lacked anti-Sm antibodies; instead, they likely contained one population of antibodies splecific for the U1 snRNP and an- Fig. 1, lane 1) , assays based on serially diluted sera can be used to assess the relative titers of anti-Ul and anti-U2 RNP antibodies. Based upon this approach and as shown in Fig. 1 , sera from patients 1, 2, and 4 (lanes S-10 and 14-16) had titers ofanti-U2 RNP greater than the titers of anti-U 1 RNP while sera from patients 5-8 (lanes [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] had greater titers of anti-Ul RNP antibodies. Serum from patient 3 had high titers of both specificities (lanes [11] [12] [13] . Diluted sera from patients 1, 2, and 4 were monospecific for U2 snRNP particles.
RNP, and with anti-Sm plus anti-Ro antibodies, respectively (lanes 3 and 4), and from the eight test sera (lanes S-28). Sera from these eight patients were also screened at dilutions of 1:100 and 1:1000. Lanes 1-22 and lanes 23-28 are from different experiments.
The diagnoses of the 229 patients whose sera were screened are shown in Table I . All eight patients with anti-U2 antibodies had rheumatic disease syndromes that included overlap features. Table II gives a more complete description of these In immunodiffusion, the four sera with high titers of anti-U2 antibodies produced a unique precipitin band that showed identity, and that had partial identity with the anti-Sm control serum, but lacked identity with an anti-U 1 RNP control. This band is likely related to the anti-U2 antibodies in these sera (25) . All eight sera produced speckled nuclear staining when tested in indirect immunofluorescence.
Protein antigens bound. To identify the specific protein antigens bound by these eight sera, we performed immunoblots using substrates enriched for either U 1 or U2 snRNPs.
HeLa cell extracts were circulated over an anti-U 1 affinity column to obtain a preparation of Ul RNP proteins (Fig. 2, stained substrate lanes). The column flow-through was then circulated over an anti-U2 column prepared with serum from patient 1 to obtain a fraction enriched in U2 snRNPs (Fig. 2,  stain) . In Fig. 2 it can be seen that a control serum containing 
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U1 U2 Ul U2 Ul U2 Ul U2 U1 U2 U1 U2 U1 U2 Ul U2 Ul U2 U1 U2 Figure 2 . Immunoblots of affinity-purified U I and U2 snRNP substrates using a serum from a patient control which contains anti-U I RNP plus anti-Sm antibodies, the eight test sera (labeled 1-8 at the top of the figure) , and a serum from a normal volunteer. The total substrate proteins, after transfer to nitrocellulose and staining with amido black, are shown at the left. The positions of the U I RNPspecific polypeptides 68K, A, and C, the U2-specific polypeptides A' and B", and the B/B polypeptides (common to the U2, U 1, and Fig. 1 when the sera are diluted) also bound the 68K and C polypeptides. Sera 1, 3, 4, 7, and 8 also bound the B'/B polypeptides in the Ul snRNP substrate lane. The anti-U2 activity of the test sera was directed against both U2-specific polypeptides A' and B". In immunoblots using the U2 snRNP substrate, sera with high titers ofanti-U2 antibodies bound A' and B" (Fig. 2, sera 1-4 ), while sera with lower titers of anti-U2 antibodies recognized only B" (sera 5-8). Sera 1, 3, and 4 also bound the U2-specific A' protein in the U1 substrate lane, indicating some contamination of this preparation with U2 snRNP proteins.
Two-dimensional immunoblots. To be certain that we were able to distinguish the U2-specific polypeptide B" from the B'/B polypeptides which migrate closely on one-dimensional gels, we performed nonequilibrium pH gradient two-dimensional gels and immunoblots using substrates eluted from an anti-Sm immunoaffinity column. These substrates contained all of the polypeptides found in the U 1 and U2 snRNPs. (Fig. 3 A) . The B'/B polypeptides were bound when the same nitrocellulose strip was reprobed with an anti-Sm serum and were clearly distinguished from B" by their more basic isoelectric points (Fig. 3 B) (26) . Although this control serum did not contain antibodies to B", this polypeptide was still visualized since antibodies from the anti-U2 serum (Fig. 3 A) remained bound. Similar immunoblots were performed with two other anti-U2 sera with identical results (data not shown).
Structural relationships ofthe A' and B" polypeptides. Previous studies had demonstrated that both the A' and B" polypeptides resided on or near the 3' end ofthe U2 RNA (39, 40) .
Since there appeared to be linkage in the immune response to these two polypeptides in our study, we investigated whether they were physically associated on the U2 RNA. As shown in experiment using antibodies that were affinity purified from immunoblots. As expected, antibodies purified from the A' band immunoprecipitated both the A' and B' polypeptides since they both were attached to the U2 RNA (lane 5); the other polypeptides of the U2 snRNP were not visualized due to the small concentration ofaffinity-purified antibodies available to perform this experiment. After ribonuclease digestion, both proteins were still bound by these anti-A' specific antibodies (lane 6) and not recovered in the supernatant (lane 7), suggesting that these two proteins were physically associated. Alternatively, they may be separated by a segment of RNA that is inaccessible to the relatively small pancreatic ribonuclease enzyme (Mr = approximately 13,600 D). As controls, antibodies eluted from a blank area of nitrocellulose or from a non-snRNP protein (lanes 8 and 9) did not bind any polypeptides.
This result could also be explained by the presence of a cross-reactive epitope on the A' and B' polypeptides. To test this possibility, we performed immunoblots using immunoaffinity-purified antibodies. As shown in Fig. 5 , antibodies eluted from the A' band only reblotted the A' polypeptide.
Thus this polypeptide had a unique epitope not shared by B', a finding consistent with previous data (26) . Additionally, antibodies eluted from B' did not recognize the A' polypeptide but did react with the A polypeptide of the Ul particle (and vice versa), consistent with the observation that these two polypeptides share a cross-reactive epitope (26, 41) .
Discussion
The present study demonstrates that sera from 8 of 229 patients with various rheumatic diseases contain antibodies that are specific for the A' and B' polypeptides of the U2 snRNP. All eight of the sera were donated by patients with features of an overlap syndrome, including three with documented myositis and three with clinical evidence for this disorder. Thus, autoimmune responses to these polypeptides appear to be particularly common in sera from patients with overlap syndromes with features of myositis.
The present work defines in more detail the patterns of autoimmune responses to the U 1 and U2 snRNP particles. We distinguished two different autoantibody systems that independently bind the A' and B' polypeptides of the U2 snRNP particle and demonstrated that these antibodies occur in an ordered hierarchy (anti-B' responses occurred in all patients, anti-A' responses occurred in a subset). Not surprisingly, sera with both specificities more effectively immunoprecipitated the native U2 particle from extracts of Hela cells and could be indentified by immunodiffusion using the appropriate control sera. The enzyme digestion studies shown in Fig. 4 Thus these findings provi body sets that target macr ther support for the coi protein particles elicit ti sponses (42) . Previous studies of t] methods for its biochei (12) (13) (14) . These studies lacked the 68K, A, and shared the B'/B and Dseries of snRNPS, and ii peptide subsequently can sponses to the U2 snRNF the description of serum polymyositis overlap syn serum, the presence of t second unique polypep Subsequently sera from f ies to the U2 particle we sera confirmed the presei this polypeptide shared ai snRNP, and demonstrate tide of the U2 snRNP pa
The association of ai gen (now known to be MCTD was first noted in in subsequent studies (20, 21 (27, 28) . Furthermore, the association of anti-U2 antibodies and overlap syndromes with features of myositis we observed in our study rests on retrospective evidence: we screened sera to identify those with 3 4 5 6
anti-U2 antibodies, and included three sera, one from an earan anti-U2 serum and using antibodies lier survey (25) and two obtained from other investigators, n by elution from polypeptides transknown to have this specificity; subsequently, we reviewed m from patient 4 (see Fig. 2 ) was used to clinical diagnoses and established the association. Although we , (lane 1) and a U2 snRNP substrate suspect the prevalence of anti-U2 autoantibodies in patients iere then used to reprobe a substrate conwith overlap syndromes is low, our method of data accumulatNP proteins (lanes 3-6). Antibodies tion precludes an exact determination. B' bands reblot both these polypeptides Several of the eight test sera bound the B'/B polypeptides dies eluted from A' only reblot A' (lane (Fig. 2 ) even though only one of these sera (serum 3) had even in area of nitrocellulose without specific weak anti-Sm activity as determined by immunoprecipitation
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target of anti-Sm antibodies remain tightly associated to one Sour additional patients with antibodanother and to their RNA after denaturation in SDS (18). ,re described (26) . Studies with these Thus, intact splicing complexes and/or partially degraded nce of B' on this snRNP, showed that snRNP particles might act as autoimmunogens to produce the n epitope with the A protein ofthe Ul ANA patterns observed here and in other studies.
d a unique epitope on the A' polypepIt is unclear why the U2 specific polypeptides (A' and B') Lrticle.
are less common autoantigens than the U 1 specific polypepntibodies to extractable nuclear antitides (68K, A, and C) or the Sm polypeptides (B'/B and D) that the anti-U 1 RNP specificity) with are shared among the U 1, U2, U4-6 snRNPs. All of these 1971 (19) and has been corroborated polypeptides are components of snRNP particles that are en-1722 gaged in the common function of processing new premessenger RNA transcripts, although the polypeptides themselves may have different stoichiometric relationships with their respective RNAs (9, 12) . Variations in their stabilities, or perhaps in their structural features, including the degree of exposure or the degree of conservation (47, 48) , are likely to be important determinants of how they function as autoantigens. The relationship of the autoantigenic epitopes on the Ul and U2 snRNPs and amino acid sequence information derived from current cloning efforts in a number of laboratories (49) (50) (51) (52) could yield important insights into fundamental mechanisms of autoimmunity.
